Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT00172185 Completed - Clinical trials for Short Bowel Syndrome

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Start date: January 10, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.

NCT ID: NCT00171860 Terminated - Clinical trials for Hypereosinophilic Syndrome

A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

Start date: September 2002
Phase: Phase 2
Study type: Interventional

The objectives of the study are: 1. Evaluation of the safety profile of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome resistant or refractory to, or intolerant of, prednisone, hydroxyurea or interferon-alpha, or untreated patients carrying the Fip1L1-PDGFRA fusion protein. 2. Evaluation of the efficacy of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome 3. Analysis of patient's blood samples for the detection of activated kinases.

NCT ID: NCT00171548 Completed - Metabolic Syndrome Clinical Trials

Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

Start date: October 2004
Phase: Phase 4
Study type: Observational

Metabolic syndrome is commonly defined as a set of risk factors and abnormalities that markedly increase the risk of cardiovascular events. Its relevance has been confirmed by a recent population-based survey of subjects aged 40-79 years indicating that the prevalence of metabolic syndrome in Italy is 34.1% if diagnosed using WHO criteria and 17.8% if diagnosed using the NCEP-ATPIII criteria. On the basis of the above considerations, the aim of this study is to promote the use of the SCORE algorithm for estimating cardiovascular risk, and to evaluate its evolution in patients with metabolic syndrome after the implementation of a multifactorial preventive strategy, with particular reference to the correction of lifestyle, hypertension and dyslipidemia.

NCT ID: NCT00171431 Terminated - Clinical trials for Irritable Bowel Syndrome (IBS-C)

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Start date: November 2004
Phase: Phase 3
Study type: Interventional

Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.

NCT ID: NCT00170937 Completed - HYPERTENSION Clinical Trials

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

Start date: November 2004
Phase: Phase 4
Study type: Interventional

The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases. The purpose of this study is to determine whether two common drugs to lower blood pressure, whether used separately or in combination, have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome.

NCT ID: NCT00169637 Completed - Clinical trials for Short Bowel Syndrome

Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome

Start date: June 2006
Phase: Phase 3
Study type: Interventional

This is a randomized controlled, parallel group, open label versus "no treatment" trial which evaluate the efficacy of rhGH on weaning off parenteral nutrition in children with short bowel syndrome.The total follow-up is 14 months; 4 months for each group after randomization; At the end of the first four months: the treated group will be followed within 6 months, the untreated group will receive compassionately rhGH for 4 months and followed-up for 6 months after the end of the treatment period.

NCT ID: NCT00167635 Completed - Clinical trials for Irritable Bowel Syndrome

Nursing Management of Irritable Bowel Syndrome:Improving Outcomes

Start date: January 2003
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is 1) to determine whether a comprehensive self-management intervention is effective in a sample that includes men and women with irritable bowel syndrome, and 2) to determine whether the comprehensive self-management intervention is as effective when delivered over the telephone as compared to a face-to-face approach.

NCT ID: NCT00167622 Completed - Clinical trials for Acute Respiratory Failure

Early Mechanical Ventilation for Guillain Barré Syndrome

Start date: April 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether early mechanical ventilation can prevent hospital acquired pneumonia in adults with Guillain Barré Syndrome.

NCT ID: NCT00166569 Recruiting - Clinical trials for Polycystic Ovary Syndrome

The Genetics of Polycystic Ovarian Syndrome

Start date: January 2003
Phase:
Study type: Observational

The goal of this study is to determine the genetic basis of polycystic ovary syndrome (PCOS). We will first look for genes in the Icelandic population, where large family trees are known and it is easier to search for genes. We will then determine whether these same genes are important in U.S. PCOS patients.

NCT ID: NCT00166452 Completed - Clinical trials for Complex Regional Pain Syndrome, Type 1

A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1

Start date: July 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if lenalidomide is a safe and effective treatment for complex regional pain syndrome type 1 (CRPS).